News Related to Ikaros

Related coverage linked through entity extraction aliases.

BMS CELMoD Mezigdomide Doubles PFS in Myeloma as FDA Reviews Iberdomide

May 29, 2026

BMS's mezigdomide doubled progression-free survival in relapsed/refractory multiple myeloma at ASCO, while the FDA reviews iberdomide with a decision due by August 17. C4 Therapeutics has dosed the first patient in its Phase 2 MOMENTUM trial of cemsidomide.

CELMoDs and CAR T-Cell Therapies Show Promise in Multiple Myeloma Treatment

Feb 27, 2026

Novel CELMoD agents are being evaluated to address T-cell exhaustion in multiple myeloma patients, while CAR T-cell therapy CARVYKTI shows longer-term survival benefits. Nearly 200,000 people in the U.S. live with this blood cancer.